The Journal of Urology
Volume 171, Issue 2, Supplement , Pages S45-S49 , February 2004

Genetic Variations in the Vitamin D Receptor, Androgen Receptor and Enzymes that Regulate Androgen Metabolism

  • DOUGLAS K. PRICE
    • ,
  • MICHAEL E. FRANKS
    • ,
  • WILLIAM D. FIGG

      Affiliations

    • Corresponding Author InformationCorrespondence: Molecular Pharmacology Section, Cancer Therapeutics Branch, National Cancer Institute, Bldg. 10, Room 5A01 MSC 1910, 9000 Rockville Pike, Bethesda, Maryland 20892 (telephone: 301-402-3622; FAX: 301-402-8606).

REFERENCES 

  1. Guyton KZ , Kensler TW , Posner GH . Cancer chemoprevention using natural vitamin D and synthetic analogs . Annu Rev Pharmacol Toxicol . 2001;41:421
  2. Konety BR , Getzenberg RH . Vitamin D and prostate cancer . Urol Clin North Am . 2002;29:95
  3. Blutt SE , Weigel NL . Vitamin D and prostate cancer . Proc Soc Exp Biol Med . 1999;221:89
  4. Issa LL , Leong GM , Eisman JA . Molecular mechanism of vitamin D receptor action . Inflamm Res . 1998;47:451
  5. Minghetti PP , Norman AW . 1,25(OH)2-vitamin D3 receptors: gene regulation and genetic circuitry . Faseb J . 1988;2:3043
  6. Schwartz GG , Hulka BS . Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis) . Anticancer Res . 1990;10:1307
  7. Lawson DE , Paul AA , Black AE , Cole TJ , Mandal AR , Davie M . Relative contributions of diet and sunlight to vitamin D state in the elderly . Br Med J . 1979;2:303
  8. Baker MR , Peacock M , Nordin BE . The decline in vitamin D status with age . Age Ageing . 1980;9:249
  9. Hanchette CL , Schwartz GG . Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation . Cancer . 1992;70:2861
  10. Braun MM , Ahlbom A , Floderus B , Brinton LA , Hoover RN . Effect of twinship on incidence of cancer of the testis, breast, and other sites (Sweden) . Cancer Causes Control . 1995;6:519
  11. Gann PH , Ma J , Hennekens CH , Hollis BW , Haddad JG , Stampfer MJ . Circulating vitamin D metabolites in relation to subsequent development of prostate cancer . Cancer Epidemiol Biomarkers Prev . 1996;5:121
  12. Nomura AM , Stemmermann GN , Lee J , Kolonel LN , Chen TC , Turner A , et al.   Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States) . Cancer Causes Control . 1998;9:425
  13. Holick MF . The photobiology of vitamin D3 in man . In:  Kumar R editors. Vitamin D: Basic and Clinical Aspects . Boston: Martimus Nijhoff; 1984;p. 197–216
  14. Stoilov I , Akarsu AN , Alozie I , Child A , Barsoum-Homsy M , Turacli ME , et al.   Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1 . Am J Hum Genet . 1998;62:573
  15. Ahonen MH , Tenkanen L , Teppo L , Hakama M , Tuohimaa P . Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) . Cancer Causes Control . 2000;11:847
  16. Corder EH , Guess HA , Hulka BS , Friedman GD , Sadler M , Vollmer RT , et al.   Vitamin D and prostate cancer: a prediagnostic study with stored sera . Cancer Epidemiol Biomarkers Prev . 1993;2:467
  17. Tuohimaa P , Lyakhovich A , Aksenov N , Pennanen P , Syvala H , Lou YR , et al.   Vitamin D and prostate cancer . J Steroid Biochem Mol Biol . 2001;76:125
  18. Konety BR , Johnson CS , Trump DL , Getzenberg RH . Vitamin D in the prevention and treatment of prostate cancer . Semin Urol Oncol . 1999;17:77
  19. Chan JM , Giovannucci E , Andersson SO , Yuen J , Adami HO , Wolk A . Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden) . Cancer Causes Control . 1998;9:559
  20. Giovannucci E . Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis . Cancer Causes Control . 1998;9:567
  21. Kelloff GJ , Johnson JR , Crowell JA , Boone CW , DeGeorge JJ , Steele VE , et al.   Approaches to the development and marketing approval of drugs that prevent cancer . Cancer Epidemiol Biomarkers Prev . 1995;4:1
  22. Lieberman R . Chemoprevention of prostate cancer: current status and future directions . Cancer Metastasis Rev . 2002;21:297
  23. Krishnan AV , Peehl DM , Feldman D . Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression . J Cell Biochem . 2003;88:363
  24. Green JE , Greenberg NM , Ashendel CL , Barrett JC , Boone C , Getzenberg RH , et al.   Workgroup 3: transgenic and reconstitution models of prostate cancer . Prostate . 1998;36:59
  25. Sharma P , Schreiber-Agus N . Mouse models of prostate cancer . Oncogene . 1999;18:5349
  26. Perez-Stable CM , Schwartz GG , Farinas A , Finegold M , Binderup L , Howard GA , et al.   The G gamma/T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089 . Cancer Epidemiol Biomarkers Prev . 2002;11:555
  27. Xue L , Lipkin M , Newmark H , Wang J . Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice . J Natl Cancer Inst . 1999;91:176
  28. Beaty MM , Lee EY , Glauert HP . Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2-dimethylhydrazine-induced colon carcinogenesis in rats fed high fat diets . J Nutr . 1993;123:144
  29. Osborn JL , Schwartz GG , Smith DC . Phase II trial of oral 1,25-dihyroxyvitamin D (calcitriol) in hormone refractory prostate cancer . Urol Oncol . 1995;1:195
  30. Gross C , Stamey T , Hancock S , Feldman D . Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) . J Urol . 1998;159:2035
  31. Beer TM , Eilers KM , Garzotto M , Egorin MJ , Lowe BA , Henner WD . Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer . J Clin Oncol . 2003;21:123
  32. Bouillon R , Okamura WH , Norman AW . Structure-function relationships in the vitamin D endocrine system . Endocr Rev . 1995;16:200
  33. Coughlin SS , Hall IJ . A review of genetic polymorphisms and prostate cancer risk . Ann Epidemiol . 2002;12:182
  34. Xu Y , Shibata A , McNeal JE , Stamey TA , Feldman D , Peehl DM . Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression . Cancer Epidemiol Biomarkers Prev . 2003;12:23
  35. Gennari L , Becherini L , Falchetti A , Masi L , Massart F , Brandi ML . Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms . J Steroid Biochem Mol Biol . 2002;81:1
  36. Jurutka PW , Remus LS , Whitfield GK , Thompson PD , Hsieh JC , Zitzer H , et al.   The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB . Mol Endocrinol . 2000;14:401
  37. Taylor JA , Hirvonen A , Watson M , Pittman G , Mohler JL , Bell DA . Association of prostate cancer with vitamin D receptor gene polymorphism . Cancer Res . 1996;56:4108
  38. Ma J , Stampfer MJ , Gann PH , Hough HL , Giovannucci E , Kelsey KT , et al.   Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians . Cancer Epidemiol Biomarkers Prev . 1998;7:385
  39. Ingles SA , Coetzee GA , Ross RK , Henderson BE , Kolonel LN , Crocitto L , et al.   Association of prostate cancer with vitamin D receptor haplotypes in African-Americans . Cancer Res . 1998;58:1620
  40. Peehl DM , Skowronski RJ , Leung GK , Wong ST , Stamey TA , Feldman D . Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells . Cancer Res . 1994;54:805
  41. Leman ES , Getzenberg RH . Effects of 1,25-dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells . J Cell Biochem . 2003;88:609
  42. Zhao XY , Ly LH , Peehl DM , Feldman D . Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells . Endocrinology . 1999;140:1205
  43. Zhao XY , Peehl DM , Navone NM , Feldman D . 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms . Endocrinology . 2000;141:2548
  44. Navone NM , Olive M , Ozen M , Davis R , Troncoso P , Tu SM , et al.   Establishment of two human prostate cancer cell lines derived from a single bone metastasis . Clin Cancer Res . 1997;3:2493
  45. Montgomery JS , Price DK , Figg WD . The androgen receptor gene and its influence on the development and progression of prostate cancer . J Pathol . 2001;195:138
  46. Irvine RA , Yu MC , Ross RK , Coetzee GA . The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer . Cancer Res . 1995;55:1937
  47. Mhatre AN , Trifiro MA , Kaufman M , Kazemi-Esfarjani P , Figlewicz D , Rouleau G , et al.   Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy . Nat Genet . 1993;5:184
  48. Makridakis NM , di Salle E , Reichardt JK . Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II . Pharmacogenetics . 2000;10:407
  49. Makridakis NM , Ross RK , Pike MC , Crocitto LE , Kolonel LN , Pearce CL , et al.   Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA . Lancet . 1999;354:975
  50. Nam RK , Toi A , Vesprini D , Ho M , Chu W , Harvie S , et al.   V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression . Urology . 2001;57:199
  51. Picado-Leonard J , Miller WL . Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21 . DNA . 1987;6:439
  52. Carey AH , Waterworth D , Patel K , White D , Little J , Novelli P , et al.   Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17 . Hum Mol Genet . 1994;3:1873
  53. Wadelius M , Andersson AO , Johansson JE , Wadelius C , Rane E . Prostate cancer associated with CYP17 genotype . Pharmacogenetics . 1999;9:635
  54. Habuchi T , Liqing Z , Suzuki T , Sasaki R , Tsuchiya N , Tachiki H , et al.   Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect . Cancer Res . 2000;60:5710
  55. Lunn RM , Bell DA , Mohler JL , Taylor JA . Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2) . Carcinogenesis . 1999;20:1727
  56. Stanford JL , Noonan EA , Iwasaki L , Kolb S , Chadwick RB , Feng Z , et al.   A polymorphism in the CYP17 gene and risk of prostate cancer . Cancer Epidemiol Biomarkers Prev . 2002;11:243
  57. Kittles RA , Panguluri RK , Chen W , Massac A , Ahaghotu C , Jackson A , et al.   Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans . Cancer Epidemiol Biomarkers Prev . 2001;10:943
  58. Waxman DJ , Attisano C , Guengerich FP , Lapenson DP . Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme . Arch Biochem Biophys . 1988;263:424
  59. Kleinbloesem CH , van Brummelen P , Faber H , Danhof M , Vermeulen NP , Breimer DD . Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man . Biochem Pharmacol . 1984;33:3721
  60. Murray GI , Taylor VE , McKay JA , Weaver RJ , Ewen SW , Melvin WT , et al.   The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer . J Pathol . 1995;177:147
  61. Rebbeck TR , Jaffe JM , Walker AH , Wein AJ , Malkowicz SB . Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 . J Natl Cancer Inst . 1998;90:1225
  62. Ando Y , Tateishi T , Sekido Y , Yamamoto T , Satoh T , Hasegawa Y , et al.   Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 . J Natl Cancer Inst . 1999;91:1587
  63. Ball SE , Scatina J , Kao J , Ferron GM , Fruncillo R , Mayer P , et al.   Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4 . Clin Pharmacol Ther . 1999;66:288
  64. Amirimani B , Walker AH , Weber BL , Rebbeck TR . RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 . J Natl Cancer Inst . 1999;91:1588
  65. Rebbeck TR . More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 . J Natl Cancer Inst . 2000;92:76
  66. Westlind A , Lofberg L , Tindberg N , Andersson TB , Ingelman-Sundberg M . Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region . Biochem Biophys Res Commun . 1999;259:201
  67. Kittles RA , Chen W , Panguluri RK , Ahaghotu C , Jackson A , Adebamowo CA , et al.   CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? . Hum Genet . 2002;110:553
  68. Paris PL , Kupelian PA , Hall JM , Williams TL , Levin H , Klein EA , et al.   Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients . Cancer Epidemiol Biomarkers Prev . 1999;8:901
  69. Kuehl P , Zhang J , Lin Y , Lamba J , Assem M , Schuetz J , et al.   Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression . Nat Genet . 2001;27:383
  70. Ingles SA , Ross RK , Yu MC , Irvine RA , La Pera G , Haile RW , et al.   Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor . J Natl Cancer Inst . 1997;89:166

PII: S0022-5347(05)62518-9

doi: 10.1097/01.ju.0000108402.60404.48

The Journal of Urology
Volume 171, Issue 2, Supplement , Pages S45-S49 , February 2004

Article Tools

* Image Usage & Resolution